Filing Details

Accession Number:
0001209191-20-055042
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-16 15:51:19
Reporting Period:
2020-10-14
Accepted Time:
2020-10-16 15:51:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1741830 Kronos Bio Inc. KRON () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1190578 C John Martin C/o Kronos Bio, Inc.
1300 So. El Camino Real, Suite 300
San Mateo CA 94402
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-10-14 914,333 $0.00 914,333 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-10-14 756,971 $0.00 1,671,304 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-10-14 205,260 $16.15 1,876,564 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-10-14 75,800 $19.00 1,952,364 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series Seed Preferred Stock Disposition 2020-10-14 866,667 $0.00 914,333 $0.00
Common Stock Series A Preferred Stock Disposition 2020-10-14 717,509 $0.00 756,971 $0.00
Common Stock Convertible Promissory Note Disposition 2020-10-14 0 $0.00 205,260 $16.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 2022-02-20 No 4 C Indirect
Footnotes
  1. Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  2. The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
  3. The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.